(Q39905453)

15 September 2017

0 references

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma (English)

1 reference

15 September 2017

0 references

0 references

5

1 reference

15 September 2017

6

1 reference

15 September 2017

Giuseppe Cabibbo

1

1 reference

15 September 2017

Giuseppe Cabibbo

2

1 reference

15 September 2017

Marco Enea

3

1 reference

15 September 2017

Massimo Attanasio

4

1 reference

15 September 2017

Calogero Cammà

7

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

15 September 2017

1 reference

15 September 2017

51

1 reference

15 September 2017

1274-1283

1 reference

15 September 2017

4

1 reference

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

15 September 2017

1 reference

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

Management of hepatocellular carcinoma

21 January 2018

1 reference

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Major achievements in hepatocellular carcinoma

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

21 January 2018

1 reference

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

21 January 2018

1 reference

Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma

21 January 2018

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

21 January 2018

1 reference

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

21 January 2018

1 reference

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma

21 January 2018

1 reference

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 January 2018

1 reference

Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

21 January 2018

1 reference

Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials

21 January 2018

1 reference

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies

21 January 2018

1 reference

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

21 January 2018

1 reference

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems

21 January 2018

1 reference

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

21 January 2018

1 reference

7 January 2021

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

1 reference

7 January 2021

Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma

1 reference

7 January 2021

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial

1 reference

7 January 2021

Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis

1 reference

7 January 2021

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23485

1 reference

15 September 2017

1 reference